"This was the largest nationwide population-based longitudinal cohort study to investigate the association between the use of ...
New data suggest that current recommendations overstate the proportion of patients who would receive significant kidney ...
The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to ...
GlobalData on MSN15d
Diabetes duration has minimal impact on SGLT2 inhibitor efficacy, as per new analysisA meta-analysis has demonstrated consistent efficacy in heart failure outcomes with SGLT2 inhibitors regardless of disease ...
Recent study highlights a significant care gap due to the underuse of SGLT2 inhibitors, despite their benefits. Canada: A ...
The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to ...
Empagliflozin, an SGLT2 inhibitor, is proven safe and effective for heart attack patients, offering a new treatment option to ...
A total of 77 suicide deaths in GLP-1 agonist users and 71 in SGLT2 inhibitor users were identified. Subgroup analyses ...
TheracosBio today announced that, in the wake of the federal government release of negotiated prices under the Medicare Drug ...
Like other drugs for heart failure, SGLT2 inhibitors were originally developed to lower blood sugar levels in patients with diabetes. But this drug soon found its way into the heart of clinics that ...
If you've recently received a diagnosis of type 2 diabetes, understanding your treatment options is an important first step.
Recurrent stroke risk was lower among patients with type 2 diabetes who used SGLT2 inhibitors within 3 months of ischemic stroke.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback